Mendus AB
5.30
SEK
+0.11
(+2.12%)
ISIN
SE0022239950
Return %
Stock
S&P 500
1Y
-5.19
14.20
3Y
-37.13
81.12
5Y
-92.35
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Erik Manting
- Full Time Employees
- 27
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Västra Trädgårdsgatan 15 Stockholm AB Sweden 111 53
- IPO Date
- Apr 22, 2013
- Website
- mendus.com
- Similar Companies
- Business
- Mendus AB (publ) (Nasdaq Stockholm: IMMU), a clinical-stage biopharmaceutical company, develops off-the-shelf, cell-based immunotherapies leveraging allogeneic dendritic cell biology to treat tumor recurrence and improve survival outcomes in cancer patients while preserving quality of life; its lead candidate vididencel (DCP-001) advances in the Phase II ADVANCE-II trial as maintenance therapy for acute myeloid leukemia (AML), the Phase II CADENCE trial combining vididencel with oral azacitidine in AML supported by the Australasian Leukaemia and Lymphoma Group, and the Phase I ALISON trial in ovarian cancer; additional pipeline assets include ilixadencel in Phase I/II for soft tissue sarcomas and a preclinical NK cell program targeting natural killer cell-based therapies. The company maintains operations in Sweden, with its primary headquarters at Västra Trädgårdsgatan 15 in Stockholm, and the Netherlands, including its main R&D center in Leiden as a wholly owned subsidiary Mendus BV; founded in 2002 as Immunicum AB (publ), it rebranded to Mendus AB (publ) in June 2022. Recent developments encompass supportive feedback from the European Medicines Agency and U.S. Food and Drug Administration on Phase 3 trial design for vididencel in AML during Q1 2025, alongside first patient enrollment in the AMLM22-CADENCE trial in February 2025; Mendus progresses large-scale GMP production of vididencel targeted for the second half of 2025 through its manufacturing alliance with NorthX Biologics, executes a directed share issue of approximately SEK 52.5 million in November 2025 to fund clinical milestones, and updates its clinical development strategy based on positive survival data from ADVANCE-II presented at the American Society of Hematology 2024 meeting.